glp-1 prescriptions growth q1 2025 The United States Agonists Weight Loss Drugs Market Size & Outlook, 2030 GLP-1 Agonists Weight Loss Drugs

Patient-Centric Approach Dedicated to providing personalized treatment plans

Experimental studies suggest that liraglutide exerts its anorexigenic but not hypoglycemic effects through CNS receptors, rather than through vagus nerve receptors [25]

Published metabolomic research shows that: Dietary components generate distinct metabolite profiles that influence oxidative stress, mitochondrial energy production, detoxification, and lipid pathways

Weight loss follows a relatively smooth curve with gradual deceleration after the first six months

In the U.S., about 6% of adults currently use GLP-1s, and 12% have used them in the past (2024 data) (Mozafariun 2025)